Henry Schein (NASDAQ:HSIC) Announces FY 2026 Earnings Guidance

Henry Schein (NASDAQ:HSIC – Get Free Report) updated its FY 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 5.420-5.480 for the period, compared to the consensus estimate of 5.540. The company issued revenue guidance of $13.8 billion-$13.9 billion, compared to the consensus revenue estimate of $13.8 billion.

Henry Schein Stock Performance

HSIC opened at $86.22 on Monday. The company has a quick ratio of 0.76, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of 23.62, a P/E/G ratio of 1.51 and a beta of 0.87. The company has a 50-day simple moving average of $85.91 and a 200 day simple moving average of $81.54. Henry Schein has a twelve month low of $68.70 and a twelve month high of $92.18.

Henry Schein (NASDAQ:HSIC – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.20. Henry Schein had a net margin of 3.07% and a return on equity of 16.39%. The business had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period last year, the firm posted $1.38 earnings per share. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. Analysts predict that Henry Schein will post 5.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HSIC. BTIG Research lifted their price target on shares of Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Monday, August 17th. Citigroup reaffirmed a “buy” rating and set a $112.00 target price (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Stifel Nicolaus set a $95.00 price objective on Henry Schein in a research note on Wednesday, August 5th. Finally, UBS Group boosted their price target on shares of Henry Schein from $94.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $93.57.

Check Out Our Latest Report on HSIC

About Henry Schein

(Get Free Report)

Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.

Read More

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.